Araceli Biosciences and Ginkgo Bioworks ( NYSE : DNA ) announced today that they will integrate the Araceli Endeavor ® high-content imaging equipment into their autonomous laboratory “Nebula” located in Boston. Araceli states that Endeavor is the fastest high-content imaging system in the world, capable of complementing the existing technologies of Nebula with cell imaging and real-time analysis capabilities, and providing researchers with large, organized datasets necessary for training and validating AI models in drug discovery.

Nebula is constructed based on Ginkgo's “Reconfigurable Automation Carts” ( RACs ). Ginkgo states that each RAC is a modular unit, integrating robotic arms, automated sample transfer, and unified control software; therefore, the equipment can be added or rearranged as the work process changes. Ginkgo indicates that dozens of scientists use over 100 RAC on Nebula to conduct real research, submit experimental plans, and receive data the following day. Nebula can autonomously process large amounts of work in parallel, operating around the clock, and requires about one-third of the space needed for traditional laboratories to accomplish the same task.

The Endeavor system is capable of scanning a 1536-well plate in less than four minutes, and has been integrated into the Nebula system based on RAC. It can operate continuously alongside ongoing experiments. With the help of the ClaireRT ™ software from Araceli, Endeavor analyzes each well during the image collection process. If a well does not meet the preset standards, the system can notify the operator or Nebula, or pause imaging to allow for issues to be corrected before the experiment continues.

Araceli Biosciences President and CEO, Matt Beaudet, stated: "Next-generation drug discovery AI requires completely different types of biological data. The laboratories themselves are undergoing changes. They now generate cell data, interpret what they see, and respond in real time. Ginkgo is achieving this through Nebula, while Araceli integrates high-resolution imaging and real-time analysis on a large scale into this process."

Ginkgo Bioworks, co-founder and CEO, and Jason Kelly stated: "Whenever you add a first-class piece of equipment to an independent laboratory, its value increases. With one's own independent laboratory, each scientist can utilize Endeavor's industry-leading high-content imaging capabilities and easily connect it with all other equipment. This is precisely what independent laboratories offer: the ability to integrate the best tools in biology into a unified software system, allowing experiments to run around the clock."

Araceli Biosciences indicates that the company develops the world's fastest high-content imaging equipment, as well as AI analysis software for automated, AI driven laboratories. Its integrated solutions can provide real-time cellular insights, enabling automated workflows to check quality and make decisions at every stage of the experiment, thereby helping biotechnology and pharmaceutical companies to expand research results more quickly and with greater certainty. For more information, see aracelibio.com.

Ginkgo Bioworks indicates that the company develops tools to help anyone design biological processes more easily. The company provides autonomous laboratories that replace manual experimental operations with robots, thereby significantly enhancing scientists' productivity. Ginkgo The company's own autonomous laboratories are also available in the form of "cloud laboratories" through its contract research services " Datapoints " and " Solutions ". For more information, see ginkgo.bio, or follow their social media accounts: X (@ Ginkgo and @Ginkgo_Biosec), Instagram (@ GinkgoBioworks ), Threads (@ GinkgoBioworks ), and LinkedIn. Ginkgo Bioworks develops infrastructure for autonomous laboratories and bio-data generation services to make experimental science more scalable and accessible. Ginkgo Bioworks claims to be a leading horizontal platform in the field of cell programming, providing flexible, end-to-end services to help companies in various markets such as food and agriculture, pharmaceuticals, industry, and specialty chemicals address challenges.

Ginkgo Bioworks also indicates that this press release contains certain forward-looking statements in the meaning of U.S. securities law, including statements regarding the capabilities and potential success of this partnership, as well as those concerning Ginkgo's independent laboratory. These forward-looking statements typically use phrases such as "believes," "may," "predicts," "potential," "expects," "anticipates," "estimates," "intends," "strategy," "future," "opportunity," "plans," "perhaps," "should," "will," "shall," "will continue," "is likely to result in," and similar expressions. Forward-looking statements are predictions, inferences, and other statements about future events based on current expectations and assumptions, and therefore involve risks and uncertainties. Various factors could lead to significant differences between actual future events and the forward-looking statements contained in this press release, including but not limited to:(i) Whether the company can achieve short-term and long-term cost savings related to the site integration plan, including whether it is possible to terminate leases or find sub-tenants for idle facilities;( ii ) Securities prices fluctuate due to a variety of factors, including changes in the highly competitive and heavily regulated industries in which they operate or intend to enter, fluctuations in the performance of competitors, as well as changes in laws and regulations that affect their business;( iii ) The company's ability to execute business plans, make forecasts, and achieve other expectations, as well as to identify and realize additional business opportunities, including its solutions and tools business;( iv ) Risk of decreased demand for synthetic biology products;(v) Uncertainty regarding passive monitoring projects and the demand for biosafety services;( vi ) Changes in the biosafety industry, including technological advancements, the emergence of new competitors, and the evolution of industry requirements, standards, and regulations;( vii ) Any outstanding or potential litigation results regarding Ginkgo;( viii ) The company's ability to achieve the expected returns on platform projects and assets and to ensure their success;( ix ) The company's capability to successfully develop genetically modified cells, bioprocesses, data packages, or other services;(x) Customer success in product development, production, or manufacturing;( xi ) The volatility and liquidity risks associated with the company holding equity in other operating entities, as well as other non-cash consideration that may be received in exchange for services;( xii ) The potential negative impact on business reorganization or the expected savings related to this did not materialize;( xiii ) There is uncertainty regarding the government's budget priorities and the funds allocated to government agencies, including the potential adverse effects of a shutdown of the U.S. government;( xiv ) Whether the company can expand its own laboratories (including Nebula) within the expected timeline and scale, increase production capacity, and further enhance its capabilities;( xv ) The speed of adoption of autonomous laboratory infrastructure in the broader life sciences and industrial biotechnology markets, and the extent to which it replaces manual experimental work;( xvi ) The actual size, structure, and growth of the target market may differ significantly from the estimates;( xvii ) The company's ability to integrate its own laboratory platform with third-party AI models and other technologies, as well as the speed at which these technologies are developed and adopted; and( xviii ) The company's ability to maintain and expand relationships with strategic partners and customers, including those mentioned in this press release, is not exhaustive. Readers should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of Ginkgo's 10-K annual report filed with the U.S. Securities and Exchange Commission (SEC) on February 26, 2026, as well as in other documents submitted from time to time to SEC. These documents list and discuss additional significant risks and uncertainties that could lead to material differences between actual events and results and those contained in the forward-looking statements. Forward-looking statements are only valid as of the date of issuance. Readers should not rely excessively on such statements, and Ginkgo assumes no responsibility and has no intention of updating or revising these forward-looking statements due to new information, future events, or other reasons. Ginkgo does not guarantee that the company will be able to achieve its expectations.

Araceli Biosciences Investor and Media Contact: [ email protected ]